Published in

Oxford University Press, Clinical and Experimental Immunology, 1(201), p. 34-39, 2020

DOI: 10.1111/cei.13419

Links

Tools

Export citation

Search in Google Scholar

The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation

Journal article published in 2020 by N. H. Servaas ORCID, J. Spierings, J. M. van Laar ORCID, A. Pandit, J. M. Laar
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Summary Systemic sclerosis (SSc) is a complex, heterogeneous autoimmune connective tissue disease. Autologous hematopoietic stem-cell transplantation (AHSCT) has emerged as a valuable treatment option for rapidly progressive diffuse cutaneous SSc (dcSSc) patients, and thus far is the only treatment that has been shown to have a long-term clinical benefit. AHSCT is thought to reintroduce immune homeostasis through elimination of pathogenic self-reactive immune cells and reconstitution of a new, tolerant immune system. However, the mechanism of action underlying this reset to tolerance remains largely unknown. In this study we review the immune mechanisms underlying AHSCT for SSc, with a focus on the role of the innate immune cells, including monocytes and natural killer (NK) cells, in restoring immune balance after AHSCT.